CN1727332A - Compound in category of aryl methylamino dithio formic ether, preparation method and application - Google Patents
Compound in category of aryl methylamino dithio formic ether, preparation method and application Download PDFInfo
- Publication number
- CN1727332A CN1727332A CN 200410054686 CN200410054686A CN1727332A CN 1727332 A CN1727332 A CN 1727332A CN 200410054686 CN200410054686 CN 200410054686 CN 200410054686 A CN200410054686 A CN 200410054686A CN 1727332 A CN1727332 A CN 1727332A
- Authority
- CN
- China
- Prior art keywords
- replace
- alkyl
- aryl
- compound
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
An antineoplastic arylmethylamino bithioformate compound, or its medicinal salt, its preparing process, the medicinal composition containing it, and its application are disclosed.
Description
Technical field
The present invention relates to a class dithiocarbamates compound or its pharmacologically acceptable salt, particularly relate to fragrant methylamino dithiocarbamate formic ether compounds or its pharmacologically acceptable salt, and preparation method thereof and in the application of preparation in the antitumor drug.
Background technology
Dithiocarbamates compound has a wide range of applications in a lot of fields, especially is commonly used for sterilant in pesticide field.Yet the research of the anti-tumor activity aspect of relevant this compounds but seldom.
Recently, people such as Gerhauser C are at Cancer Research 57,272-278, report in 1997, from cress, isolate a kind of isosulfocyanate compound Brassinium, this compound has stronger tumor prevention effect, by the further structure of modification to this compound, has found the dithiocarbamates compound Sulforamate that the tumor prevention effect is stronger.
Summary of the invention
The dithiocarbamates compound or its pharmacologically acceptable salt that the purpose of this invention is to provide general formula (I):
Wherein, Ar is selected from the aryl or the heteroaryl of unsubstituted or various replacements, and described aryl or heteroaryl preferentially are selected from unsubstituted or replacement, for example C
1-C
6Alkyl, C
1-C
6Alkoxyl group, halogen, SO
3R, NO
2Or R ' R " N-CH
2-replace phenyl, naphthyl, contain 1-3 and be selected from N, heteroatomic five yuan, the hexa-atomic or fused ring heterocycle aryl of O or S, wherein, R is selected from H, C
1-C
6Alkyl or C
6-C
10Aryl (as benzene, naphthalene etc.), R ', R " be identical or different C
1-C
6Alkyl, halogen can be F, Cl, Br etc., and the five-membered ring aryl can be furans, thiophene, pyrroles, imidazoles etc.;
R
1Be selected from H or replacement or do not replace C
1-C
12Alkyl replaces or does not replace C
2-C
12Unsaturated group (as alkenyl or alkynyl) replaces or does not replace C
6-C
20Aryl, aralkyl or alkaryl replace or do not replace C
5-C
15Heterocyclic radical or heterocyclic radical alkyl replace or do not replace C
3-C
15Cycloalkyl or cycloalkylalkyl, the carbochain of these groups can be inserted the heteroatoms that is selected among N, O and the S, perhaps R
1Can connect together with the annular atoms of Ar forms ring, constitutes condensed ring with Ar;
R
2Be selected from-(CH
2)
n-R
3,-CH
2-R
4,-(CH
2)
m-COR
5Or-(CH
2)
m-COCO
2R
6,
Wherein, n=0-4, R
3For O or S for acetal radical or ketal group, the alcohol that wherein forms described acetal radical or ketal group is C
1-C
6Aliphatic monobasic alcohol or dibasic alcohol, the aldehydes or ketones that forms described acetal radical or ketal group is C
1-C
6The fat aldehydes or ketones;
R
4Be selected from the aryl or the heteroaryl of unsubstituted or various replacements, for example, described aryl or heteroaryl are selected from unsubstituted or C
1-C
6Alkyl, C
1-C
6Alkoxyl group, halogen, SO
3R, NO
2Or R ' R " N-CH
2-replace phenyl, naphthyl, contain 1-3 and be selected from N, heteroatomic five yuan, the hexa-atomic or fused ring heterocycle aryl of O or S, wherein, R is selected from H, C
1-C
6Alkyl or C
6-C
10Aryl, R ', R " be identical or different C
1-C
6Alkyl, halogen can be F, Cl, Br etc., and the five-membered ring aryl can be furans, thiophene, pyrroles, imidazoles etc.;
R
5Be selected from and replace or do not replace C
1-C
6Alkyl (linearity or branching) replaces or does not replace C
6-C
10Aryl (as benzene, naphthalene etc.), or replace or do not replace C
3-C
10Heteroaryl;
Work as R
1Be H, R
2For-(CH
2)
m-COR
5Or-(CH
2)
m-COCO
2R
6The time, R
2With R
1Circularize an accepted way of doing sth (III) compound, wherein m=1-3.
R
6Be selected from H or replacement or not replacement, linearity or branching C
1-C
10Alkyl, preferred C
1-C
6Alkyl.
Preferably, Ar is selected from unsubstituted or replaces, for example C
1-C
6Alkyl, C
1-C
6Alkoxyl group, halogen, SO
3R, NO
2Or R ' R " N-CH
2-replace phenyl, naphthyl, contain 1-3 and be selected from N, heteroatomic five yuan, the hexa-atomic or fused ring heterocycle aryl of O or S, wherein, R is selected from H, C
1-C
6Alkyl or C
6-C
10Aryl (as benzene, naphthalene etc.), R ', R " be identical or different C
1-C
6Alkyl, halogen can be F, Cl, Br etc., and the five-membered ring aryl can be furans, thiophene, pyrroles, imidazoles etc.;
R
1Be selected from H or replacement or do not replace C
1-C
8Alkyl replaces or does not replace C
2-C
8Unsaturated group (as alkenyl or alkynyl) replaces or does not replace C
6-C
12Aryl, aralkyl or alkaryl replace or do not replace C
3-C
12Heterocyclic radical or heterocyclic radical alkyl replace or do not replace C
3-C
12Cycloalkyl or cycloalkylalkyl, the carbochain of these groups can be inserted the heteroatoms that is selected among N, O and the S, perhaps R
1Can connect together with the annular atoms of Ar forms ring, constitutes condensed ring with Ar;
R
1More preferably be selected from H or replacement or do not replace C
1-C
6Alkyl replaces or does not replace C
2-C
6Alkenyl replaces or does not replace C
6-C
10Aryl, or R
1Circularize an accepted way of doing sth (II) compound with Ar,
Substituent A
1And A
2Substituting group in the cotype (I) among the Ar, i.e. C for example
1-C
6Alkyl, C
1-C
6Alkoxyl group, halogen, SO
3R, NO
2Or R ' R " N-CH
2-, R wherein, R ' and R " as defined above.
Another object of the present invention provides a kind of method for preparing this compounds.This method comprises allows ArCH
2NH-R
1, CS
2And R
2-X reaction in appropriate solvent (as acetone, dimethyl formamide, N,N-DIMETHYLACETAMIDE, ether solvent) under the existence of an alkali metal salt or alkaline earth salt (for example potassiumphosphate, salt of wormwood, cesium carbonate etc.),
Wherein:
Ar is selected from the aryl or the heteroaryl of unsubstituted or various replacements, and described aryl or heteroaryl preferentially are selected from unsubstituted or replace, for example C
1-C
6Alkyl, C
1-C
6Alkoxyl group, halogen, SO
3R, NO
2Or R ' R " N-CH
2-replace phenyl, naphthyl, contain 1-3 and be selected from N, heteroatomic five yuan, the hexa-atomic or fused ring heterocycle aryl of O or S, wherein, R is selected from H, C
1-C
6Alkyl or C
6-C
10Aryl (as benzene, naphthalene etc.), R ', R " be identical or different C
1-C
6Alkyl, halogen can be F, Cl, Br etc., and the five-membered ring aryl can be furans, thiophene, pyrroles, imidazoles etc.;
R
1Be selected from H or replacement or do not replace C
1-C
12Alkyl replaces or does not replace C
2-C
12Unsaturated group (as alkenyl or alkynyl) replaces or does not replace C
6-C
20Aryl, aralkyl or alkaryl replace or do not replace C
5-C
15Heterocyclic radical or heterocyclic radical alkyl replace or do not replace C
3-C
15Cycloalkyl or cycloalkylalkyl, the carbochain of these groups can be inserted the heteroatoms that is selected among N, O and the S, perhaps R
1Can connect together with the annular atoms of Ar forms ring, constitutes condensed ring with Ar;
X is a leavings group, Cl for example, Br, I etc.;
R
2Be selected from-(CH
2)
n-R
3,-CH
2-R
4,-(CH
2)
m-CO
R5 or-(CH
2)
m-COCO
2R
6,
Wherein, n=0-4, R
3For O or S for acetal radical or ketal group, the alcohol that wherein forms described acetal radical or ketal group is C
1-C
6Aliphatic monobasic alcohol or dibasic alcohol, the aldehydes or ketones that forms described acetal radical or ketal group is C
1-C
6The fat aldehydes or ketones;
R
4Be selected from the aryl or the heteroaryl of unsubstituted or various replacements, described aryl or heteroaryl are selected from unsubstituted or C
1-C
6Alkyl, C
1-C
6Alkoxyl group, halogen, SO
3R, NO
2Or R ' R " N-CH
2-replace phenyl, naphthyl, contain 1-3 and be selected from N, heteroatomic five yuan, the hexa-atomic or fused ring heterocycle aryl of O or S, wherein, R is selected from H, C
1-C
6Alkyl or C
6-C
10Aryl, R ', R " be identical or different C
1-C
6Alkyl, halogen can be F, Cl, Br etc., and the five-membered ring aryl can be furans, thiophene, pyrroles, imidazoles etc.;
R
5Be selected from and replace or do not replace C
1-C
6Alkyl (linearity or branching) replaces or does not replace C
6-C
10Aryl (as benzene, naphthalene etc.), or replace or do not replace C
3-C
10Heteroaryl;
R
6Be selected from H or replacement or not replacement, linearity or branching C
1-C
10Alkyl, preferred C
1-C
6Alkyl.
The temperature of reaction is not special restriction, can be 0-100 ℃, preferred 10-40 ℃, and more preferably about room temperature (25 ℃).
The process of reaction can detect by TLC to be monitored.Reacted product can by filter, concentrate, post-treating methods such as extraction, recrystallization or column chromatography process.
Raw material A r-CH
2-NH-R
1, R
2-X all can be purchased or be synthetic by currently known methods in the art.
The 3rd purpose of the present invention provides the application of compound or its salt in the preparation antitumor drug of following general formula:
Wherein each group definition and preferred definition are as implied above.
Another object of the present invention provides the pharmaceutical composition that contains this compounds.Compound or pharmaceutically acceptable salt thereof of the present invention can be used as activeconstituents and one or more pharmaceutically acceptable carriers, vehicle or thinner are formed the pharmaceutical composition with antitumor action.The content of compound in pharmaceutical composition of its formula of (I) for example can be 1-95wt%, is preferably 20-90wt%.
Pharmaceutical composition of the present invention also routinely technology make capsule, tablet, oral liquid, injection or transfusion formulation, and make controlled release or slow-released system administration as required.
The compound of general formula of the present invention (I) can use alone or use with the form of composition.
The dosage of the compound of general formula of the present invention (I) decides according to the factors such as weight of patient age, body weight, the course of disease, disease.For example, as a reference, under the situation of oral dosage form, the consumption of compound of the present invention can be 0.1-12mg/kg/d, and under the situation of injection type, compound amount of the present invention can be 0.1-8mg/kg/d.
Purpose compound of the present invention has very strong antitumor action and has showed low toxicity.
Embodiment
The following examples are used to further specify the present invention, but do not limit the present invention in any way:
The preparation of embodiment 1 compound 1
(compound 1)
With 2-furylamine (0.49g, 5 * 10
-3Mol) be dissolved in acetone (or dimethyl formamide) (5mL) in, stir and to add anhydrous phosphoric acid potassium (1.06g, 5 * 10 down
-3Mol), dithiocarbonic anhydride (1mL, excessive), behind the 30min, add 2-bromacetal (0.99g, 5 * 10
-3Mol) acetone soln.Behind the stirring at room 2h, stopped reaction.Filter, filtrate concentrates, and adds 20mL water, uses ethyl acetate extraction.Ethyl acetate layer is washed and with after the Calcium Chloride Powder Anhydrous drying, rotary evaporation concentrates, and gets weak yellow liquid compound 1 (1.32g, 91%).
Ultimate analysis: C
12H
19NO
3S
2Calculated value (%): C 49.80, and H 6.62, and N 4.84; Measured value (%): C 49.56, and H 6.50, and N 5.12.
1H-NMR(CDCl
3，δ)：1.18(t，6H)，3.29(d，2H)，3.52～3.75(m，4H)，4.64(t，1H)，4.86(d，2H)，6.34～6.36(m，2H)，7.38(t，1H)，8.51(br，1H)。
The preparation of embodiment 2 compounds 2
(compound 2)
Compound 2 synthetic, post-treating method is identical with compound 1, just the 2-bromacetal is replaced with o-chloro benzyl chloride.
Productive rate: 93%, weak yellow liquid.Ultimate analysis: C
13H
12ClNOS
2Calculated value (%): C 52.43, and H 4.06, and N 4.70; Measured value (%): C 52.64, and H 4.46, and N 5.01.
1H-NMR(CDCl
3，δ)4.58～4.88(m，2H)，6.31～6.34(m，2H)，7.17～7.56(m，7H)。
The preparation of embodiment 3 compounds 3
(compound 3)
Compound 3 synthetic, post-treating method is identical with compound 1, just the 2-bromacetal is replaced with Mono Chloro acetone.
Productive rate: 96%.The rhombus white crystal, 75～77 ℃ of mp.Ultimate analysis: C
9H
11NO
2S
2Calculated value (%): C 47.14, and H 4.83, and N 6.11; Measured value (%): C 47.38, and H 4.82, N6.18.FAB (MH
+): calculated value 230.3; Measured value 230.1.
The preparation of embodiment 4 compounds 4
(compound 4)
Compound 4 synthetic, post-treating method is identical with compound 1, just the 2-furylamine is replaced with benzylamine.
Yellow oily liquid, yield: 83%.
1H-NMR(300MHz，CDCl
3)：δ＝1.12(t，6H)，3.31(d，2H)，3.49～3.71(m，4H)，4.63(t，1H)，4.88(t，2H)，7.30～7.39(m，5H)，8.36(br，1H).
13C?NMR(75MHz，CDCl
3)：δ＝196.96，136.06，128.83，128.26，128.06，102.42，63.22，51.03，38.87，15.02.
Anal.Calcd?for?C
14H
21NO
2S
2：C，56.15；H，7.07；N，4.68.Found：C，56.07；H，7.00；N，4.71.
The preparation of embodiment 5 compounds 5
(compound 5)
Compound 5 synthetic, post-treating method is identical with compound 4, just the 2-bromacetal is replaced with 2-(2-bromotrifluoromethane)-1,3-dioxolane.
Yellow oily liquid, yield: 65%.
1H-NMR(300MHz，CDCl
3)：δ＝2.06～2.17(m，2H)，3.34(t，2H)，3.79～3.96(m，4H)，4.89～4.97(m，3H)，7.31～7.37(m，5H).
Anal.Calcd?for?C
13H
17NO
2S
2：C，55.09；H，6.05；N，4.94.Found：C，55.25；H，6.01；N，5.02.
The preparation of embodiment 6 compounds 6
(compound 6)
Compound 6 synthetic, post-treating method is identical with compound 5, just benzylamine is replaced with 3, the 4-dichloro-benzylamine.
Yellow oily liquid, yield: 53%.
1H-NMR(300MHz，CDCl
3)：δ＝2.05～2.14(m，2H)，3.35(t，2H)，3.83～4.02(m，4H)，4.89～4.99(m，3H)，7.16～7.42(m，3H).EI-MS(m/z)：351[M]
+，159[M-192]
+.
The preparation of embodiment 7 compounds 7
(compound 7)
Compound 7 synthetic, post-treating method is identical with compound 5, just benzylamine is replaced with 4-Methoxybenzylamine.
Yellow oily liquid, yield: 71%.
1H-NMR(300MHz，CDCl
3)：δ＝2.03～2.12(m，2H)，3.33(t，2H)，3.81～4.00(m，7H)，4.82(d，2H)，4.96(t，1H)，6.86～6.90(m，2H)，7.21～7.27(m，3H).
Anal.Calcd?for?C
14H
19NO
3S
2：C，53.65；H，6.11；N，4.47.Found：C，53.45；H，6.14；N，4.28.
(compound 8)
The preparation of embodiment 8 compounds 8
Compound 8 synthetic, post-treating method is identical with compound 5, just benzylamine is replaced with the benzyl methylamine.
Yellow oily liquid, yield: 95%.
1H-NMR(300MHz，CDCl
3)：δ＝2.11～2.17(m，2H)，3.25(s，2H)，3.45，(s，3H)，3.88～4.03(m，4H)，5.00(s，2H)，5.38(s，1H)，7.22～7.32(m，5H).
Anal.Calcd?for?C
14H
19NO
2S
2：C，56.53；H，6.44；N，4.71.Found：C，56.29；H，6.44；N，4.57.
The preparation of embodiment 9 compounds 9
(compound 9)
Compound 9 synthetic, post-treating method is identical with compound 5, just benzylamine is replaced with the furfuryl methylamine.
Yellow oily liquid, yield: 84%.
1H-NMR(300MHz，CDCl
3)：δ＝2.07～2.13(m，2H)，3.33～3.52(m，5H)，3.82～4.04(m，4H)，4.98(t，2H)，5.30(s，1H)，6.35(d，2H)，7.38(s，1H).
Anal.Calcd?for?C
12H
17NO
3S
2：C，50.15；H，5.96；N，4.87.Found：C，49.97；H，5.85；N，4.80.
The preparation of embodiment 10 compounds 10
(compound 10)
Compound 10 synthetic, post-treating method is identical with compound 4, just the 2-bromacetal is replaced with ethyl bromide acetone.
Faint yellow prismatic crystal, mp111～112 ℃, yield 57%.1.02(3H，t，Me)，3.34(1H，br，OH)，3.44(1H，d，ArCH
2)，3.66(1H，q，MeCH
2)，3.86(1H，d，ArCH
2)，3.88(1H，q，MeCH
2)，4.76(1H，d，SCH
2)，5.01(1H，d，SCH
2)，7.28(4H，m，Ar).
13C-NMR(CDCl
3，δ)：13.47，37.84，48.30，62.23，96.59，127.07，127.65，127.96，135.91，167.73，196.85.
The preparation of embodiment 11 compounds 11
(compound 11)
Compound 11 synthetic, post-treating method is identical with compound 10, just benzylamine is replaced with the 2-furylamine.
Yellow liquid, yield 93%.
1H-NMR(CDCl
3，δ)：1.13(3H，t，Me)，3.34(1H，d，ArCH
2)，3.67(1H，d，ArCH
2)，3.89(1H，m，MeCH
2)，4.16(1H，m，MeCH
2)，4.61(1H，d，SCH
2)，4.81(1H，br，OH)，5.19(1H，d，SCH
2)，6.24(1H，dd，Ar)，6.31(1H，d，Ar)，7.26(1H，dd，Ar)；
13C-NMR(CDCl
3，δ)：13.70，38.0241.0364.46，94.78，110.62，110.68，142.27148.24，169.51198.03。
The preparation of embodiment 12 compounds 12
(compound 12)
Compound 12 synthetic, post-treating method is identical with compound 10, just benzylamine is replaced with chlorobenzylamine.
Water white transparency, be hexagonal plate crystal, 116～117 ℃ of mp, yield 59%.
1H-NMR(CDCl
3，δ)：1.09(3H，t，Me)，3.38(1H，d，ArCH
2)，3.53(1H，q，MeCH
2)，3.72(1H，d，ArCH
2)，4.01(1H，q，MeCH
2)，4.46(1H，d，SCH
2)，4.91(1H，br，OH)，5.40(1H，d，SCH
2)，7.25～7.30(4H，m，Ar)
13C-NMR(CDCl
3，δ)：13.53，37.90，47.55，64.59，94.58，128.40，130.04，133.62，169.68，198.92.
The preparation of embodiment 13 compounds 13
(compound 13)
Compound 13 synthetic, post-treating method is identical with compound 10, just benzylamine is replaced with a chlorobenzylamine.
Colourless plate crystal, mp112～113 ℃, yield 78%.
1H-NMR(CDCl
3，δ)：1.11(3H，t，Me)，3.40(1H，d，ArCH
2)，3.54(1H，q，MeCH
2)，3.73(1H，d，ArCH
2)，4.02(1H，q，MeCH
2)，4.43(1H，d，SCH
2)，4.93(1H，br，OH)，5.43(1H，d，SCH
2)，7.25(4H，m，Ar).
13C-NMR(CDCl
3，δ)：15.52，37.92，47.69，64.49，94.58，126.76，128.08，128.49，129.56，134.25，137.11，169.66，199.02.
The preparation of embodiment 14 compounds 14
(compound 14)
Compound 14 synthetic, post-treating method is identical with compound 10, just benzylamine is replaced with 4-Methoxybenzylamine.
Colourless needle crystal, mp101～102 ℃, yield 74%.
1H-NMR(CDCl
3，δ)：1.07(3H，t，Me)，3.36(1H，d，ArCH
2)，3.49(1H，q，MeCH
2)，3.67(1H，d，ArCH
2)，3.78(3H，s，CH
3O)，3.96(1H，q，MeCH
2)，4.45(1H，d，SCH
2)，5.30(1H，br，OH)，5.40(1H，d，SCH
2)，6.82(2H，m，Ar)，7.29(2H，m，Ar).
13C-NMR(CDCl
3，δ)：13.54，29.66，37.94，47.77，55.28，63.99，94.84，113.56，127.21，130.17，159.27，169.51，198.39.
The preparation of embodiment 15 compounds 15
(compound 15)
Compound 15 synthetic, post-treating method is identical with compound 10, just benzylamine is replaced with NSC 158269.
Colourless needle crystal, mp122～123 ℃, yield 32%.
1H-NMR(CDCl
3，δ)：1.08(3H，t，Me)，3.38(1H，d，ArCH
2)，3.52(1H，q，MeCH
2)，3.69(1H，d，ArCH
2)，3.99(1H，q，MeCH
2)，4.46(1H，d，SCH
2)，4.90(1H，br，OH)，5.42(1H，d，SCH
2)，6.98(2H，m，Ar)，7.35(2H，m，Ar).
13C-NMR(CDCl
3，δ)：13.56，29.69，37.91，47.49，64.35，94.58，115.07，115.24，130.49，130.56，161.41，163.37，169.72，198.83.
The preparation of embodiment 16 compounds 16
(compound 16)
Compound 16 synthetic, post-treating method is identical with compound 10, just benzylamine is replaced with tetrahydroisoquinoline.
White, needle-shaped crystals, mp.69～70 ℃, yield 11%.
Embodiment 17
With above-claimed cpd 50mg of the present invention, after the adding tween 80 stirs hydrotropy, add injection physiological saline 5ml, sterilization filling is made injection after filtration.
Embodiment 18
With above-claimed cpd 100mg of the present invention and lactose 100mg, after Mierocrystalline cellulose 180mg and Magnesium Stearate 10mg mixed evenly, technology was made tablet routinely.
The biological activity test of compound and interpretation of result
1. anti-tumor activity testing method
1. mtt assay: tetrazolium reduction method
2. srb assay: sulphonyl rhodamine B protein staining method
2. activity experiment data and interpretation of result
Test compound 1-16 inhibiting rate to five kinds of tumor cell lines (HL-60 human leukemia, BGC-823 people's cancer of the stomach, Bel-7402 people's liver cancer, Hela human cervical carcinoma, MDA-MB-435 human breast carcinoma) under 0.1 μ M, 1 μ M, the 10 μ M concentration respectively with in vitro method, found all to have better antitumor activity and lower toxicity.
Wherein, when compound 1 is 10 μ M in concentration, the inhibiting rate of Bel-7402 people's liver cancer (srb assay), Hela human cervical carcinoma (srb assay) cell strain is respectively 72.57% (P＜0.01), 73.46% (P＜0.01).
When compound 7 is 10 μ M in concentration, the inhibiting rate of HL-60 human leukemia (srb assay), BGC-823 people's cancer of the stomach (srb assay), MDA-MB-435 human breast carcinoma (srb assay) cell strain 51.95% (P＜0.01), 85.56% (P＜0.01), 97.45% (P＜0.01) have been reached respectively.
When compound 15 is 10 μ M in concentration, inhibiting rate to Bel-7402 people's liver cancer (srb assay), Hela human cervical carcinoma (srb assay) cell strain and PC-3MIE8 human prostata cancer is respectively 62.3% (P＜0.01), 83.4% (P＜0.01) and 64.0% (P＜0.01).
Benzyl dithiocarbamates compound of the present invention has very strong antitumor action and lower toxicity, is the potential antitumor drug of a class.
Claims (9)
1, the dithiocarbamates compound of general formula (I) or its pharmacologically acceptable salt:
Wherein, Ar is selected from the aryl or the heteroaryl of unsubstituted or various replacements;
R
1Be selected from H or replacement or do not replace C
1-C
12Alkyl replaces or does not replace C
2-C
12Alkenyl or alkynyl replaces or does not replace C
6-C
20Aryl, aralkyl or alkaryl replace or do not replace C
5-C
15Heterocyclic radical or heterocyclic radical alkyl replace or do not replace C
3-C
15Cycloalkyl or cycloalkylalkyl, the carbochain of these groups can be inserted the heteroatoms that is selected among N, O and the S, perhaps R
1Can connect together with the annular atoms of Ar forms ring, constitutes condensed ring with Ar;
R
2Be selected from-(CH
2)
n-R
3,-CH
2-R
4,-(CH
2)
m-COR
5Or-(CH
2)
m-COCO
2R
6,
Wherein, n=0-4, R
3For O or S for acetal radical or ketal group, the alcohol that wherein forms described acetal radical or ketal group is C
1-C
6Aliphatic monobasic alcohol or dibasic alcohol, the aldehydes or ketones that forms described acetal radical or ketal group is C
1-C
6The fat aldehydes or ketones;
R
4Be selected from aryl or heteroaryl unsubstituted or that replace;
R
5Be selected from and replace or do not replace C
1-C
6Alkyl (linearity or branching) replaces or does not replace C
6-C
10Aryl (as benzene, naphthalene etc.), or replace or do not replace C
3-C
10Heteroaryl;
R
6Be selected from H or replacement or not replacement, linearity or branching C
1-C
10Alkyl;
Work as R
1Be H, R
2For-(CH
2)
m-COR
5Or-(CH
2)
m-COCO
2R
6The time, R
2Can with R
1Circularize an accepted way of doing sth (III) compound, wherein m=1-3.
2, dithiocarbamates compound as claimed in claim 1 or its pharmacologically acceptable salt is characterized in that:
Ar is selected from unsubstituted or the phenyl, the naphthyl that replace, contain 1-3 and be selected from N, heteroatomic five yuan, the hexa-atomic or fused ring heterocycle aryl of O or S;
R
1Be selected from H or replacement or do not replace C
1-C
8Alkyl replaces or does not replace C
2-C
8Unsaturated thiazolinyl or alkynyl replace or do not replace C
6-C
12Aryl, aralkyl or alkaryl replace or do not replace C
3-C
12Heterocyclic radical or heterocyclic radical alkyl replace or do not replace C
3-C
12Cycloalkyl or cycloalkylalkyl, the carbochain of these groups can be inserted the heteroatoms that is selected among N, O and the S, or R
1Circularize an accepted way of doing sth (II) compound with Ar,
Substituent A
1And A
2Be selected from C
1-C
6Alkyl, C
1-C
6Alkoxyl group, halogen, SO
3R, NO
2Or R ' R " N-CH
2-, wherein R is selected from H, C
1-C
6Alkyl or C
6-C
10Aryl, R ', R " be identical or different C
1-C
6Alkyl.
3, compound or pharmaceutically acceptable salt thereof as claimed in claim 1, wherein, Ar is selected from furans, thiophene, pyrroles, imidazoles.
4, compound or pharmaceutically acceptable salt thereof as claimed in claim 1, wherein, Ar is the 2-furyl, R
1=H, R
2Be 2-acetal base.
5, compound or pharmaceutically acceptable salt thereof as claimed in claim 1, wherein, Ar is a p-methoxyphenyl, R
1=H, n=2, R
3Be 2-(1, the 3-dioxolane)-Ji.
6, compound or pharmaceutically acceptable salt thereof as claimed in claim 1, wherein R
4Be selected from unsubstituted or C
1-C
6Alkyl, C
1-C
6Alkoxyl group, halogen, SO
3R, NO
2Or R ' R " N-CH
2-replace phenyl, naphthyl, contain 1-3 and be selected from N, heteroatomic five yuan, the hexa-atomic or fused ring heterocycle aryl of O or S, wherein, R is selected from H, C
1-C
6Alkyl or C
6-C
10Aryl, R ', R " be identical or different C
1-C
6Alkyl, halogen are F, Cl, Br, and the five-membered ring aryl for example is furans, thiophene, pyrroles, imidazoles.
7, the method for compound of preparation claim 1, this method comprise allows Ar-(CH
2)-NH-R
1, CS
2And R
2-X reacts in inert solvent in the presence of an alkali metal salt or alkaline earth salt,
Wherein:
Ar is selected from the aryl or the heteroaryl of unsubstituted or various replacements, and described aryl or heteroaryl preferentially are selected from unsubstituted or replace, for example C
1-C
6Alkyl, C
1-C
6Alkoxyl group, halogen, SO
3R, NO
2Or R ' R " N-CH
2-replace phenyl, naphthyl, contain 1-3 and be selected from N, heteroatomic five yuan, the hexa-atomic or fused ring heterocycle aryl of O or S, wherein, R is selected from H, C
1-C
6Alkyl or C
6-C
10Aryl (as benzene, naphthalene etc.), R ', R " be identical or different C
1-C
6Alkyl, halogen can be F, Cl, Br etc., and the five-membered ring aryl can be furans, thiophene, pyrroles, imidazoles etc.;
R
1Be selected from H or replacement or do not replace C
1-C
12Alkyl replaces or does not replace C
2-C
12Unsaturated alkyl replaces or does not replace C
6-C
20Aryl, aralkyl or alkaryl replace or do not replace C
5-C
15Heterocyclic radical or heterocyclic radical alkyl replace or do not replace C
3-C
15Cycloalkyl or cycloalkylalkyl, the carbochain of these groups can be inserted the heteroatoms that is selected among N, O and the S, perhaps R
1Can connect together with the annular atoms of Ar forms ring, constitutes condensed ring with Ar;
X is a leavings group;
R
2Be selected from-(CH
2)
n-R
3,-CH
2-R
4,-(CH
2)
m-COR
5Or-(CH
2)
m-COCO
2R
6,
Wherein, n=0-4, R
3For O or S for acetal radical or ketal group, the alcohol that wherein forms described acetal radical or ketal group is C
1-C
6Aliphatic monobasic alcohol or dibasic alcohol, the aldehydes or ketones that forms described acetal radical or ketal group is C
1-C
6The fat aldehydes or ketones;
R
4Be selected from aryl or heteroaryl unsubstituted or that replace;
R
5Be selected from and replace or do not replace C
1-C
6Alkyl (linearity or branching) replaces or does not replace C
6-C
10Aryl (as benzene, naphthalene etc.), or replace or do not replace C
3-C
10Heteroaryl;
R
6Be selected from H or replacement or not replacement, linearity or branching C
1-C
10Alkyl.
8, the application of the compound or its salt of any one of claim 1-5 in the preparation antitumor drug.
9, contain the compound or its salt of claim 1 and the pharmaceutical composition of pharmaceutically acceptable carrier.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100546869A CN100551907C (en) | 2004-07-27 | 2004-07-27 | Virtue methylamino dithiocarbamate formic ether compounds and its production and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100546869A CN100551907C (en) | 2004-07-27 | 2004-07-27 | Virtue methylamino dithiocarbamate formic ether compounds and its production and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1727332A true CN1727332A (en) | 2006-02-01 |
| CN100551907C CN100551907C (en) | 2009-10-21 |
Family
ID=35926878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100546869A Expired - Fee Related CN100551907C (en) | 2004-07-27 | 2004-07-27 | Virtue methylamino dithiocarbamate formic ether compounds and its production and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100551907C (en) |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101899011A (en) * | 2009-05-26 | 2010-12-01 | 北京大学 | Dithiocarbamates compound, preparation method and application thereof |
| WO2011131135A1 (en) * | 2010-04-21 | 2011-10-27 | 北京大学 | Heteroaryl (alkyl) dithiocarbamate compounds, preparation methods and uses thereof |
| CN102657647A (en) * | 2012-04-06 | 2012-09-12 | 澳门大学 | Application of IC-4 in antiangiogenesis |
| CN103443090A (en) * | 2010-12-16 | 2013-12-11 | 阿彻丹尼尔斯米德兰德公司 | Preparation of aminomethyl furans and alkoxymethyl furan derivatives from carbohydrates |
| CN103508930A (en) * | 2012-06-25 | 2014-01-15 | 北京大学 | Bis(aminodithioformate)-1,3-propane diester compound, and synthesis method, pharmaceutical composition and use thereof |
| CN104817490A (en) * | 2015-05-13 | 2015-08-05 | 北京大学 | Novel aminodithioformate compounds, and preparation method and application thereof |
| CN105085350A (en) * | 2014-04-18 | 2015-11-25 | 北京大学 | Dithiocarbamic acid allyl ester compound, preparation method and uses thereof |
| CN106146487A (en) * | 2015-04-27 | 2016-11-23 | 北京大学 | Pyridylmethyl dithiocarbonic acid hetero-aromatic ring alkyl esters compound and its production and use |
| CN106432208A (en) * | 2015-08-10 | 2017-02-22 | 北京大学 | (Aminosulfonyl)ethyl dithiocarbamate compounds, and preparation method and use thereof |
| CN107200720A (en) * | 2016-03-17 | 2017-09-26 | 北京大学 | A kind of brilliant II type materials of 990207-22-1, its preparation method and its pharmaceutical composition and purposes |
| CN107200719A (en) * | 2016-03-17 | 2017-09-26 | 北京大学 | A kind of brilliant VII type materials of 990207-22-1, its preparation method and its pharmaceutical composition and purposes |
| CN107226789A (en) * | 2017-05-09 | 2017-10-03 | 北京大学 | Dithiocarbamates compound, its preparation method and the purposes in antineoplastic is prepared |
| CN110683975A (en) * | 2019-10-23 | 2020-01-14 | 成都理工大学 | Synthesis method of dialkyl amino alkyl dithioformate |
| CN111349033A (en) * | 2018-12-20 | 2020-06-30 | 杜剑平 | Derivative broad-spectrum antitumor drug based on disulfiram structure and preparation method thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2972627A (en) * | 1958-03-03 | 1961-02-21 | Monsanto Canada Ltd | Substituted benzylesters of substituted benzyldithiocarbamic acids |
| US5814646A (en) * | 1995-03-02 | 1998-09-29 | Eli Lilly And Company | Inhibitors of amyloid beta-protein production |
| US6747061B2 (en) * | 2000-03-21 | 2004-06-08 | Atherogenics, Inc. | N-substituted dithiocarbamates for the treatment of biological disorders |
-
2004
- 2004-07-27 CN CNB2004100546869A patent/CN100551907C/en not_active Expired - Fee Related
Cited By (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101899011A (en) * | 2009-05-26 | 2010-12-01 | 北京大学 | Dithiocarbamates compound, preparation method and application thereof |
| CN101899011B (en) * | 2009-05-26 | 2013-01-16 | 北京大学 | Dithiocarbamates compound, preparation method and application thereof |
| WO2011131135A1 (en) * | 2010-04-21 | 2011-10-27 | 北京大学 | Heteroaryl (alkyl) dithiocarbamate compounds, preparation methods and uses thereof |
| CN102234271A (en) * | 2010-04-21 | 2011-11-09 | 北京大学 | Aryl (alkyl) amino dithio formate compounds, and preparation method and application thereof |
| CN102234271B (en) * | 2010-04-21 | 2015-06-10 | 北京大学 | Aryl (alkyl) amino dithio formate compounds, and preparation method and application thereof |
| CN103443090A (en) * | 2010-12-16 | 2013-12-11 | 阿彻丹尼尔斯米德兰德公司 | Preparation of aminomethyl furans and alkoxymethyl furan derivatives from carbohydrates |
| CN103443090B (en) * | 2010-12-16 | 2016-08-24 | 阿彻丹尼尔斯米德兰德公司 | Aminomethyl-furan and alkoxy methyl furan derivatives is prepared from carbohydrate |
| CN102657647A (en) * | 2012-04-06 | 2012-09-12 | 澳门大学 | Application of IC-4 in antiangiogenesis |
| CN103508930A (en) * | 2012-06-25 | 2014-01-15 | 北京大学 | Bis(aminodithioformate)-1,3-propane diester compound, and synthesis method, pharmaceutical composition and use thereof |
| CN103508930B (en) * | 2012-06-25 | 2016-01-27 | 北京大学 | Two (aminodithioformic acid)-1,3-propylene diester compounds and synthetic method, pharmaceutical composition and purposes |
| CN105085350B (en) * | 2014-04-18 | 2017-09-19 | 北京大学 | Aminodithioformic acid allyl ester type compound and its production and use |
| CN105085350A (en) * | 2014-04-18 | 2015-11-25 | 北京大学 | Dithiocarbamic acid allyl ester compound, preparation method and uses thereof |
| CN106146487A (en) * | 2015-04-27 | 2016-11-23 | 北京大学 | Pyridylmethyl dithiocarbonic acid hetero-aromatic ring alkyl esters compound and its production and use |
| CN106146487B (en) * | 2015-04-27 | 2019-05-10 | 北京大学 | Pyridylmethyl dithiocarbonic acid hetero-aromatic ring alkyl esters compound and its preparation method and application |
| CN104817490B (en) * | 2015-05-13 | 2017-10-13 | 北京大学 | Dithiocarbamates compound and preparation method and application |
| CN104817490A (en) * | 2015-05-13 | 2015-08-05 | 北京大学 | Novel aminodithioformate compounds, and preparation method and application thereof |
| CN106432208B (en) * | 2015-08-10 | 2019-12-13 | 北京大学 | amino dithioformic acid (sulfamoyl) ethyl ester compound and preparation method and application thereof |
| CN106432208A (en) * | 2015-08-10 | 2017-02-22 | 北京大学 | (Aminosulfonyl)ethyl dithiocarbamate compounds, and preparation method and use thereof |
| CN107200719A (en) * | 2016-03-17 | 2017-09-26 | 北京大学 | A kind of brilliant VII type materials of 990207-22-1, its preparation method and its pharmaceutical composition and purposes |
| CN107200719B (en) * | 2016-03-17 | 2019-08-30 | 北京大学 | A kind of crystalline substance VII type substance of 990207-22-1, its preparation method and its pharmaceutical composition and purposes |
| CN107200720B (en) * | 2016-03-17 | 2019-10-11 | 北京大学 | A kind of brilliant II type substance, its preparation method and its pharmaceutical composition and purposes |
| CN107200720A (en) * | 2016-03-17 | 2017-09-26 | 北京大学 | A kind of brilliant II type materials of 990207-22-1, its preparation method and its pharmaceutical composition and purposes |
| CN107226789A (en) * | 2017-05-09 | 2017-10-03 | 北京大学 | Dithiocarbamates compound, its preparation method and the purposes in antineoplastic is prepared |
| CN107226789B (en) * | 2017-05-09 | 2019-11-08 | 北京大学 | Dithiocarbamates compound, preparation method and purposes in the preparation of antitumor drugs |
| CN111349033A (en) * | 2018-12-20 | 2020-06-30 | 杜剑平 | Derivative broad-spectrum antitumor drug based on disulfiram structure and preparation method thereof |
| CN110683975A (en) * | 2019-10-23 | 2020-01-14 | 成都理工大学 | Synthesis method of dialkyl amino alkyl dithioformate |
| CN110683975B (en) * | 2019-10-23 | 2021-04-09 | 成都理工大学 | Synthesis method of dialkyl amino alkyl dithioformate |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100551907C (en) | 2009-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1264840C (en) | 8-methoxy-(1,2,4) triazolo (1,5-A) pyridine derivatives and their use as adenosine receptor ligands | |
| CN1727332A (en) | Compound in category of aryl methylamino dithio formic ether, preparation method and application | |
| CN1269821C (en) | Polymorphs of an epothilone analog | |
| CN100335461C (en) | Arylsulfonanilide ureas | |
| US10829452B2 (en) | Histone methyltransferase inhibitors | |
| CN1955183A (en) | 20-bit esterified camptothecine derivate, its preparation method and drug composite and use | |
| CN1365972A (en) | Indole derivatives and its anticancer usage | |
| CN1072652C (en) | Substd. benzoylaminothiazole derivatives and drugs containing same | |
| CN1711260A (en) | Pyridopyrimidinone compounds, method for production thereof and medicaments comprising the same | |
| CN1256687A (en) | Prodrug forms of ribonucleotide reductase inhibitors 3-AP and 3-AMP | |
| CN1035821C (en) | 4-deoxy-4-epipodophyllotoxin derivatives or pharmaceutically acceptable salt thereof | |
| CN1322205A (en) | Derivatives of isosorbid mononitrate, utilization as vasodilator agents with reduced tolerance | |
| CN1184209C (en) | Chuanxiong alkoxide derivative and its preparation and medicinal composition containing it and use thereof | |
| CN1254475C (en) | 5-methoxy-8-aryl-[1,2,4]triazolo[1,5-a]pyridine derivatives as adenosine receptor antagonists | |
| CN1227538A (en) | Pharmaceutical composition containing 4-oxo-butynic acid | |
| CN1042935C (en) | Chemical compounds | |
| CN1931869A (en) | Derivative of 5-deoxy-5-fluoro cytidine and its prepn process and use | |
| CN1071167A (en) | Perhydro--carotene 1H-pyrido [1, the 2-a] pyrazine compounds that neuroplegic 2-replaces | |
| CN101054383A (en) | Bromodihydroartemisinin and preparation method thereof | |
| CN1199931C (en) | Naphthalene alizarin derivatives, preparing method and use thereof | |
| CN101044117A (en) | 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-7-ethynyl-3-quinolinecarbonitriles for the treatment of ischemic injury | |
| CN1037179C (en) | 1,4-benzoxazino derivatives | |
| CN1761668A (en) | 7-imino derivatives of camptothecin having antitumor activity | |
| CN1319971C (en) | Camptothecine derivatives and their use | |
| CN1445217A (en) | Substitutional ramification of tetrahydro-isoquinoline, as well as its preparing method and its medication compound containing them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20091021 Termination date: 20130727 |